Vor Biopharma Inc Total Liabilities
Vor Biopharma Inc total liabilities. Based on the latest financial reports, Vor Biopharma Inc (VOR) has total liabilities worth $681.25 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check VOR cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Vor Biopharma Inc (2018–2025)
Total liabilities of Vor Biopharma Inc from 2018 to 2025. This chart illustrates how Vor Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data.
Vor Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Vor Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guizhou Broadcasting&TV Info
SHG:600996
|
China | CN¥12.24 Billion |
|
Shenzhen Hui Chuang Da Technology Co.Ltd
SHE:300909
|
China | CN¥1.46 Billion |
|
Shinva Medical Instrument Co Ltd
SHG:600587
|
China | CN¥6.91 Billion |
|
Bank Islam Malaysia Bhd
KLSE:5258
|
Malaysia | RM94.68 Billion |
|
China Communications Services Corporation Limited
F:CMW
|
Germany | €87.59 Billion |
|
Aevis Victoria SA
SW:AEVS
|
Switzerland | CHF1.34 Billion |
|
Neuberger Berman Next Generation Connectivity Fund Inc
NYSE:NBXG
|
USA | $13.86 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Vor Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Vor Biopharma Inc's balance sheet.
Liquidity & Leverage Metrics
Vor Biopharma Inc Total Liabilities Ratios Explained
Vor Biopharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vor Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vor Biopharma Inc (2018–2025)
The table below shows the annual total liabilities of Vor Biopharma Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $628.44 Million | +1259.46% |
| 2024-12-31 | $46.23 Million | -21.79% |
| 2023-12-31 | $59.10 Million | +21.22% |
| 2022-12-31 | $48.76 Million | +85.21% |
| 2021-12-31 | $26.33 Million | -4.74% |
| 2020-12-31 | $27.64 Million | +1164.27% |
| 2019-12-31 | $2.19 Million | -71.88% |
| 2018-12-31 | $7.77 Million | -- |
About Vor Biopharma Inc
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with Re… Read more